Evidence mapPaperPMID 38825614Full record

ArticleThe Journal of the Egyptian Public Health Association2024

Framework for developing cost-effectiveness analysis threshold: the case of Egypt.

Ahmad N Fasseeh, Nada Korra, Baher Elezbawy, Amal S Sedrak, Mary Gamal, Randa Eldessouki, Mariam Eldebeiky, Mohsen George, Ahmed Seyam, Asmaa Abourawash and 4 more

Erratum issuedAbstract read
In one paragraph

Article in The Journal of the Egyptian Public Health Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Rare disease challenges and potential actions in the Middle East.International journal for equity in health · 2025
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Ahmad N FasseehFaculty of Pharmacy Alexandria University, Alexandria, Egypt.
Nada KorraSyreon Middle East, Alexandria, Egypt. nada.korra@syreon.eu.ORCID http://orcid.org/0000-0003-0611-3789
Baher ElezbawySyreon Middle East, Alexandria, Egypt.
Amal S SedrakDepartment of Public Health, Cairo University, Cairo, Egypt.
Mary GamalEgyptian Authority for Unified Procurement, Medical Supply and Technology Management, Cairo, Egypt.
Randa EldessoukiDepartment of Community Health, Fayoum University, Fayoum, Egypt.
Mariam EldebeikyEgyptian Authority for Unified Procurement, Medical Supply and Technology Management, Cairo, Egypt.
Mohsen GeorgeUniversal Health Insurance Authority, Cairo, Egypt.
Ahmed SeyamUniversal Health Insurance Authority, Cairo, Egypt.
Asmaa AbourawashEgyptian Drug Authority, Cairo, Egypt.
Ahmed Y KhalifaWorld Health Organization Representative Office, Cairo, Egypt.
Mayada ShaheenRoche, Cairo, Egypt.
Sherif AbazaSyreon Middle East, Alexandria, Egypt.
Zoltán KalóCenter for Health Technology Assessment, Semmelweis University, Budapest, Hungary.

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundCost-effectiveness analyses rarely offer useful insights to policy decisions unless their results are compared against a benchmark threshold. The cost-effectiveness threshold (CET) represents the maximum acceptable monetary value for achieving a unit of health gain. This study aimed to identify CET values on a global scale, provide an overview of using multiple CETs, and propose a country-specific CET framework specifically tailored for Egypt. The proposed framework aims to consider the globally identified CETs, analyze global trends, and consider the local structure of Egypt's healthcare system.

methodsWe conducted a literature review to identify CET values, with a particular focus on understanding the basis of differentiation when multiple thresholds are present. CETs of different countries were reviewed from secondary sources. Additionally, we assembled an expert panel to develop a national CET framework in Egypt and propose an initial design. This was followed by a multistakeholder workshop, bringing together representatives of different governmental bodies to vote on the threshold value and finalize the recommended framework.

resultsThe average CET, expressed as a percentage of the gross domestic product (GDP) per capita across all countries, was 135%, with a range of 21 to 300%. Interestingly, while the absolute value of CET increased with a country's income level, the average CET/GDP per capita showed an inverse relationship. Some countries applied multiple thresholds based on disease severity or rarity. In the case of Egypt, the consensus workshop recommended a threshold ranging from one to three times the GDP per capita, taking into account the incremental relative quality-adjusted life years (QALY) gain. For orphan medicines, a CET multiplier between 1.5 and 3.0, based on the disease rarity, was recommended. A two-times multiplier was proposed for the private reimbursement threshold compared to the public threshold.

conclusionThe CET values in most countries appear to be closely related to the GDP per capita. Higher-income countries tend to use a lower threshold as a percentage of their GDP per capita, contrasted with lower-income countries. In Egypt, experts opted for a multiple CET framework to assess the value of health technologies in terms of reimbursement and pricing.

Indexed as

CETCost-effectiveness thresholdCost-effectiveness threshold multiplierEgyptIncremental relative QALY gainMultiple thresholds

Identifiers

PMID38825614
PMCPMC11144683

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.